We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Sana Biotechnology Inc. (NASDAQ:SANA) stands ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes spiking to 54 times the daily average. The surge followed highly ...

The cuts come as the biotech narrows its focus again. Last year, Sana dropped a heart failure program but kept investing in ex vivo candidates targeting CD19, CD22 and BCMA, an in vivo CD19 ...

Two Biotechs Poised For Big Moves On Monday (Sana Biotechnology | Lineage Cell Therapeutics) Catalyst: Invited six-month ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Sana Biotechnology, Inc. (NASDAQ:SANA ...

Sana isn’t giving up on cancer completely, though. The company said it will continue with SC262, a CD22-directed allogeneic CAR T currently in a phase 1 study for patients with refractory B-cell ...

Summary. Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR ...

Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced significant moves in its stock performance, attracting investor ...

SANA was launched to pioneer a particular aspect of DNA-based therapies. This is new and revolutionary. Read why the therapy will likely to take time to mature.

On Friday, Jefferies initiated coverage on Sana Biotechnology stock (NASDAQ: SANA) with a Buy rating and set a price target of $7.00.The stock, currently trading at $2.66, has shown strong ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Sana Biotechnology Inc.

Sana Biotechnology, Inc. (NASDAQ:SANA) is up 58.90% year-to-date. Overall SANA ranks 7th on our list of the biotech stocks that are skyrocketing so far in 2025.